As the trading year 2025 draws to a close, the cannabis sector presents a confusing picture for the average investor. On Dec.

After years of muted growth and battered stock prices, the sector finally began showing signs of life as long-awaited regulatory progress moved closer to reality. Earlier this month, President Trump ...

While Tilray stock gained over 40% on Friday, this cannabis company is a better buy if the U.S. reclassifies marijuana in ...

Today, Dec. 18, 2025, investors are weighing Tilray’s fresh U.S. medical push and sector volatility after federal cannabis rescheduling.

As of Friday, December 12, Organigram Global Inc.’s OGI share price has surged by 8.35%, which has investors questioning if this is right time to sell.

Tilray Brands stock jumped 27.5% on December 16 following Trump's marijuana reclassification comments and analyst upgrades.

Despite a declining share price over the last few years, Canada-based Aurora Cannabis ACB has staged a strong rally this year, all thanks to encouraging third-quarter fiscal 2025 (year ending March ...

Tilray's stock recently underwent a 1:10 reverse split, and President Trump signed an EO to reschedule cannabis to Schedule ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Once considered a darling of the cannabis sector, shares of Tilray Brands TLRY have steadily declined over the past few years due to regulatory hurdles and intensifying competition. After becoming one ...

Tilray Stock surged 35x on U.S. cannabis reform hopes. Learn what’s driving gains, risks ahead and what investors should ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...